This undiscovered Stock is one of the most attractive that i ever recommended . Valuation is only 22 Million they have $12.6 million in Cash and they have lots of Products on the Market plus new Product launches expected within 6 months . The growing Revenue is likely to hit $16 million this year and there are only 4.3 million shares outstanding .This low float stock could hit $50 (= around $215 Million valuation) especially if they turn profitable which is expected for next Year .GL Sonoma Pharma (Nasdaq: SNOA) Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15 Shares Out : 4.3 Million Presentation http://ir.sonomapharma.com/common/d...maPharma_Investor_presentation_13June2017.pdf Fact Sheet http://files.shareholder.com/downlo...-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf Driving to commercial EBITDAS breakeven, without dilution Grow current product portfolio with all sales people •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016 Launch 3 New Products –our product pipeline –one every other quarter •Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018 Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending. We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability. Regulatory Approvals and Clearances To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States. Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
They got another FDA approval for a new Product 2 weeks ago for which there was no press release because of competitive reasons , and many more Approvals expected in Brazil this year and may in Asia as well .This Stock is more than terrible underpriced with a laughable valuation of around $23 million . Management bought some shares in last days http://openinsider.com/search?q=snoa Transcript of the conference last week https://seekingalpha.com/article/40...scal-q1-2018-results-earnings-call-transcript Dermatology prescriptions filled for the first quarter were up 66% over last year and up 24% even versus the March 2017 quarter. Our growing sales team now totals 30 sales reps and 5 managers. All reps have been trained, are out in the field generating prescriptions, and we are pleased to see the team hitting new weekly sales records for prescriptions filled at the pharmacy counter almost every week. From a clinical trial perspective, we saw a publication of two studies, describing the benefits of Celacyn, our prescription scar management product, and for Sebuderm for the treatment of facial and scalp seborrheic dermatitis. Both studies are available online, in print and are great tools for our growing sales force when speaking with our customers, the dermatologists. Our profit center businesses, which we define as our international business, acute care, animal health and our contract lab testing, are all on track for profitable growth for our full fiscal year. And finally, our cash is healthy and we have almost no debt. As Bob and I discuss often, it's a great time to be running this growing company with a dedicated team, all pushing towards the same goals and objectives. Switching gears, a brief look ahead. Loyon, our skin descaling product, licensed from a German pharma company, was recently approved by the FDA and is on track for a launch in October. You may have seen, we just received our 17th FDA approval last week for a new product and a new indication. For competitive reasons, we're not in a position to discuss this product or the timing for the launch. But suffice it to say that we should have an active nine months ahead with the FDA. In Brazil, the regulatory equivalent of the FDA, which is Anvisa, asked us for more information on our pending dermatology products in the June timeframe. We've already answered their questions and provided all requested information. We now expect up to seven new dermatology product approvals – and I'm going to repeat that, not launches, but approvals – specifically for the Brazilian dermatology market this fall. As you'll no doubt remember, Brazil has become the world's third-largest market for beauty products after the US and Japan. And in plastic surgery and in dermatology procedures, Brazil is now the world's second-biggest market after the US. Additionally, we have a handful of new approvals pending in the Middle East and in China. And we look forward to providing you with more information on our international dermatology growth soon. So, in closing, we had a strong quarter due to our team's focus on our execution. We are well positioned for the remainder of this year and beyond.
New Fact Sheet .... http://files.shareholder.com/downlo...-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf Ø Pure play dermatology-focused company, building multi-technology platform Ø Products based on core Microcyn®Technology and in-licensing Ø Addressable dermatitis market of 16.5 million prescriptions or ~$1.5+ billion, with good pricing flexibility and profitability Ø Double-digit US product revenue growth providing affordable, unique & effective products –launching one per quarter
This ultra low float stock is brutally undervalued which tradingjust a few pennies above Book Value .Fantastic entry point here this stock is definitely one of the cheapest in the Pharma Sector .GL Sonoma Pharma (Nasdaq: SNOA) Marketcap: 19.6 Million Cash: $12.6 Million Price: $4.55 Book Value: $4.32 Annual Revenue on track to hit $16 Million Shares Out : 4.3 Million Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017 http://pr.report/78EFCjq0 As of 6/30/17, the Company reported $3.8M in total revenue for Q1 FY18, with product revenues up 49% year-over-year driven by growth in US dermatology and acute care markets and in products sold to new owner of Latin American assets, and with approximately $12.6M in cash on hand and minimal debt. On an EV/R basis, Sonoma currently trades at 0.2x vs. the median of its peers at 34.5x based on FY18 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See full report for additional details. Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis https://finance.yahoo.com/news/sonoma-pharmaceuticals-announces-u-commercialization-080500194.html
Hey guys if you own shares of this low float stock then please put a high GTC sell order in like $20 to prevent your shares from being borrowed to short and more important your shares will not be available on the market this is good because this helps the stock to make even bigger jumps on good news . Thans and good luck How to Prevent your Shares Holdings from being Shorted http://www.contracts-for-difference.com/Borrowing-lending-shares.html
new presentation http://ir.sonomapharma.com/common/d...e=SonomaPharma_Investor_presentation_2017.pdf Sales Plan to Achieve Profitability •6-9 month sales ramp to breakeven for sales force investment Added 13 field sales reps and 1 sales manager •Total of 30 field sales reps and 5 senior sales managers •Add/ subdivide new territories Launch 3 New Products –one every six months •Loyon and Ceramax extensions Grow current product portfolio with all sales people •Alevicyn, SebuDerm, Ceramax, Celacyn & Mondoxyne Grow with Price Increases •Expect to increase dermatology product prices by 10% to 20% in 2017 Revenue and cash from new partnerships
This company looks very interesting; in particular at the current low levels. Bought some shares today. Hopefully good things to come.
In the case of yet another strong growth in revenue similar to the last quarter SNOA will move higher again. The second quarter 2018 results will be released on November 9, 2017.
Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products Brazilian Ministério da Saúde Approves Marketing of Sonoma Pharmaceuticals' Products: Lasercyn™, Gramaderm®, Epicyn™ and Pediacyn™ Brazilian Dermatology Market Second Largest in the World Behind the United States PETALUMA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of regulatory approvals by the Brazilian Ministério da Saúde for seven of Sonoma's non-steroidal and non-antibiotic topical dermatology products: Gramaderm® Hydrogel - intended as a skin cleanser after treatment of mild to moderate acne. Gramaderm® - intended as a skin cleanser in a hydrogel vehicle after treatment of mild to moderate acne. Epicyn™ - intended as a scar treatment. Pediacyn™ - intended as an atopic dermatitis treatment. Pediacyn™ Gel -intended as an atopic dermatitis treatment in a gel vehicle. Lasercyn™ - intended as a skin cleanser following cosmetic procedures such as laser skin resurfacing. Lasercyn™ Hydrogel - intended as a skin cleanser in a hydrogel vehicle following cosmetic procedures such as laser skin resurfacing. "My Brazilian counterparts now have treatment options that can either replace or complement the standard protocols. In my practice I use Sonoma's products for healing and as a steroid-sparing agent, anti-pruritic and anti-inflammatory," said Dr. Miriam Bettencourt, assistant clinical professor of dermatology at the University of Nevada and adjunct professor of dermatology at Touro University in Las Vegas. "Having studied medicine in Brazil and with many of my colleagues practicing dermatology in Brazil, Sonoma's new approvals should provide additional non-steroidal and non-antibiotic alternatives much like I use in here in the United States." Sonoma Pharmaceuticals is currently seeking to partner with a Brazilian healthcare company relative to licensing these newly approved products in the Brazilian dermatology space. "We see the Brazilian dermatology market as being highly lucrative in terms of ongoing ramping revenue," said Bruce Thornton, Sonoma's VP of international sales. "Brazilian dermatologists are cutting edge when it comes to general dermatology and aesthetic procedures, and the addition of seven new hypochlorous acid-based products provides new alternatives for physicians worried about the side effects of topical steroids and resistance issues with the overuse of antibiotics."
Great News out today ... Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products https://finance.yahoo.com/news/sonoma-pharmaceuticals-receives-brazilian-approvals-114500685.html
2nd Quarter results today after the close. Hopefully they will indicate a further positive business development.
